Take stock of H1 global biopharmaceutical and technological fields, 10 financing opportunities, 3 seats for China

Gen, an authoritative global biotechnology media, recently released the financing report of biopharmaceutical, diagnostic and therapeutic technology companies in the early stage of the first half of 2018 According to the report, in 2018h1, a total of 18 biopharmaceutical, diagnostic and therapeutic companies raised or exceeded US $100 million The total financing amount of the top 10 companies reached 3 billion US dollars, of which the financing amount of the 10th company was 200 million US dollars, which reflected that biopharmaceutical, diagnosis and treatment new technology is still a very hot venture capital field, especially the total investment in biopharmaceutical has doubled compared with the same period last year It is particularly noteworthy that among the top 10 financing companies, three Chinese biopharmaceutical companies are listed, including cornerstone pharmaceutical, tengshengbo pharmaceutical and Tianjing bio, which is also a trend of a large number of funds flowing into Asia Exclusive the following are the top 10 financing introductions in the first half of this year: 1 Financing amount of Moderna therapeutics: 625 million US dollars announced on February 1 (round g, $500 million), May 3 (round h, $125 million) financing purpose: to further promote the research and development of messenger RNA (mRNA) new drugs in the pipeline: Moderna Therapeutics is a clinical stage biopharmaceutical company founded in Cambridge, Massachusetts in 2011 It focuses on the development of innovative therapeutic drugs and vaccine products based on mRNA The company is a pioneer in the development of mRNA drugs The created mRNA technology platform is a new in vivo drug model, which can produce therapeutic proteins or antibodies in patients' cells It is expected to provide a superior alternative to the existing protein drug model for a wide range of diseases Since its establishment, modern company has established the industry-leading mRNA technology platform and rich pipeline assets At present, there are 19 kinds of drugs under research, 10 of which have entered human clinical practice, with indications covering oncology, rare diseases, cardiovascular, infectious diseases and other fields Round g financing aims to further promote the research and development of new messenger RNA (mRNA) in the pipeline Round h financing aims to support the expansion of the 2-year cooperation project with MSD to develop and commercialize a new personalized cancer vaccine based on mRNA Round g financing includes new investment institutions and existing investors, including adia's wholly-owned subsidiaries, Singapore's EDBI, BB biotech AG, Swiss Bank of Baosheng, Sequoia Capital China Round h financing comes from MSD 2 Allogene therapeutics financing amount: 411.8 million US dollars announcement time: April 3, April 19 financing purpose: support the continuous development of "universal" car-t therapy in the pipeline introduction: allogene therapeutics is a new cell therapy company headquartered in California, USA, focusing on the development of allogeneic car-t therapy for blood cancer and solid tumor The company's management team is one of its highlights: its founders and directors are several former executives of kit pharmaceutical, a car-t pioneer "Allogeneic" car-t therapy, also known as "universal" car-t therapy, does not need to repeat the complex and time-consuming process of extracting immune cells from patients, in vitro editing and transformation, in vitro expansion, infusion back to patients It can obtain immune cells from healthy donors in advance and prepare them When patients have needs, it can be used at any time, saving a long time Preparation and transportation process Allogene's product line includes 16 pre clinical car-t assets received from Pfizer and car-t therapy ucart19 in phase I clinical Pfizer holds a 25% stake in allogen The financing is round a financing, with TPG, Vida ventures, Bellco capital, the office of the chief investment officer of the University of California, Gilead and Pfizer participating in the financing 3 Grail financing amount: US $300 million announcement time: May 21 financing purpose: to support the development and validation of cancer early detection products in clinical research projects introduction: grail is a liquid biopsy Unicorn born in Illumina, California, USA since its establishment in 2016, it has been widely concerned by the industry The company aims to achieve its vision of reducing cancer deaths globally by screening for cancer at an early stage Grail plans to look for clues of circulating tumor DNA (ctDNA) in the blood of cancer patients without symptoms, so as to diagnose cancer as early as possible In order to achieve this goal, the clinical trials launched by the company are one of the largest clinical projects so far, and two trials (CCGA, strive) have invested more than US $1 billion to ensure sufficient samples At the same time, with unprecedented breadth and depth, the company sequenced these patient samples with high intensity, and analyzed them with powerful modern data science, in order to find the real key clinical signals from the complex noise for the early diagnosis of cancer This financing is round C financing, which is participated by a large number of Chinese capital The leading investor is Huiqiao capital Tonghe Yucheng and Hillhouse capital also participate in the leading investment In addition, well-known institutions at home and abroad, such as LanChi capital, China Merchants Securities International, CRF investment, Huangpu River capital (HPR), ICBC international, Sequoia Capital China, and yaomingcode, participated in the investment 4 Viela bio financing amount: US $282.25 million announcement time: February 28, March 15 financing purpose: to complete phase II clinical, development and exploration of innovative therapy of inebilizumab: viela Bio is located in Gaithersburg, Maryland It is a biopharmaceutical company separated from MedImmune, a global research and Development Department of biological products under AstraZeneca, a British pharmaceutical giant It focuses on the field of inflammation and autoimmune diseases The independent viela bio has obtained three preclinical candidate drugs and three new drugs under clinical research from MedImmune, of which the fastest advancing one is inebilizumab, which is currently in phase IIB clinical development for the treatment of neuromyelitis optica (NMO) The drug has obtained orphan drug qualification in the United States and the European Union This financing is round a financing, led by a consortium composed of Tonghe Yucheng, Boyu capital and Hillhouse capital In addition, Temasek and SIRONA capital also participate in this round of investment After the financing, AstraZeneca remains the largest minority shareholder of viela bio 5 Financing amount of cstone pharmaceuticals: US $260 million time: May 9, 2018 financing purpose: to promote clinical research and product line expansion of cs1001 and other products under research Introduction: Keystone pharmaceutical is an innovative biopharmaceutical enterprise founded in 2016 Headquartered in Suzhou, it focuses on the development and joint treatment of tumor immune drugs The treatment fields include tumor, cardiovascular, rheumatoid arthritis, blood diseases and autoimmune diseases At present, cornerstone pharmaceutical has created a rich product line containing more than 10 products under research, four of which have successively launched clinical trials at home and abroad In the field of tumor immunotherapy, cornerstone pharmaceutical is the only domestic pharmaceutical company with PD1, PD-L1 and CTLA4 target drugs at the same time This round of financing is round B, led by sovereign wealth fund GIC, Sequoia Capital China fund, Yunfeng fund, Tonghe Yucheng capital, CITIC industry fund, Taikang Insurance Group, arch venture partners, Hillhouse capital, King Star capital, 3W Partners, avict and Hillhouse capital participate in the investment, and the existing investors Yuanhe origin, Boyu capital and Yucheng capital continue to follow the investment 6 Financing amount of brii Biosciences: US $260 million announcement time: May 24, 2018 financing purpose: accelerate the development of infectious disease drugs in China Introduction: Tengsheng Biosciences is a bio cutting-edge company committed to meet the needs of Chinese patients and public health An important strategic cooperation relationship has been reached with many enterprises to speed up the development of infectious disease drugs in China, and help the development of China's public health system through advanced technology and data, so as to benefit the vast number of patients The company has obtained the exclusive rights and interests of four kinds of innovative drugs for infectious diseases in Greater China through cooperation with vir biotechnology, a leading innovative drug R & D enterprise in the United States At the same time, the company has signed a memorandum of understanding with Alibaba health, the first digital data sharing cooperation model, and with Wuxi apptec and Wuxi appbio respectively Through strategic cooperation, with first-class R & D technology and disruptive digital and data applications, we hope to accelerate the development and marketing of innovative drugs in China May 24 is also the day when Tengsheng boyao was officially established This round of financing is led by arch venture partners, Tonghe Yucheng capital, Boyu capital, Yunfeng fund, Sequoia Capital and LanChi capital 7 Celularity financing amount: US $250 million announcement time: February 15, 2018 financing purpose: accelerate the research and development of placenta stem cell and tissue regeneration therapy Introduction: celularity is a placental stem cell company located in Warren, New Jersey It is separated from celgene, a US biotech giant Since its establishment, celularity has been widely concerned by the industry Celularity has its own research and development of cutting-edge technology and intellectual property rights to use placenta power The company's product development is an innovative biotechnology platform based on placental stem cells, which can avoid ethical disputes on embryonic stem cells Because placenta tissue contains nearly ten times as many stem cells as cord blood, its economic potential is immeasurable At present, celularity's medical portfolio includes wound bioremediation products, immunotherapy adjuvants, allogeneic car-t / NK products, placental cell therapy products, etc., and holds more than 800 placental stem cell patents This round of financing is led by Xinji, and other investment participants include United therapeutics, Sorrento therapeutics, homan longevity, geneting group, the Dreyfus family office, section 32, heritage group 8 Financing amount of i-mab biopharma: US $220 million announcement time: June 29 financing purpose: to promote the research and development of several best in class and first in class innovative biological drugs Introduction: Tianjing biology, formerly known as Sanjing biology, was founded at the end of 2014 It is a research and development company based in China and facing the global development of innovative antibody drugs, focusing on the field of tumor immunity and autoimmune disease treatment With its advantages in target biology, antibody molecular engineering research and development and translational medicine research, the company is rapidly promoting the internationally competitive project pipeline Up to now, there are more than 10 biological drugs under research and cooperation with biotechnology companies including genexine, morphasys AG, Huiling pharmaceutical, global pharmaceutical companies and top pharmaceutical R & D outsourcing companies including Yaoming bio and tiger pharmaceutical The financing is round C financing, led by Hony investment, with participation of Hillhouse capital, Hopu investment, CDH investment, Huiqiao capital and Singapore based EDBI The existing investors, Kangqiao capital and Tianshili capital, continue to follow the investment Huaxing capital acted as the exclusive financial consultant of this financing 9 Somalogic financing amount: US $200 million announcement time: January 3 financing purpose: accelerate the company to become a global leader in digital analysis of precision healthcare Introduction: somalogic is a new proteomics company located in Colorado, USA, which is introducing a new concept of digital accurate health management It measures thousands of protein data of human body through proteomics rather than gene data, which is provided based on proteomics data